Working… Menu

Biorepository for Precision Genomics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02587026
Recruitment Status : Terminated (Study team has decided to close enrollment, and all subjects are being rolled into a different clinical trial: Total Cancer Care)
First Posted : October 27, 2015
Last Update Posted : November 13, 2020
Information provided by (Responsible Party):
Bryan Schneider, Indiana University

Tracking Information
First Submitted Date October 8, 2015
First Posted Date October 27, 2015
Last Update Posted Date November 13, 2020
Actual Study Start Date August 27, 2015
Actual Primary Completion Date July 7, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: October 26, 2015)
Biorepository for precision genomics [ Time Frame: From time of patient consent (day 1) to time of sample collection (which can occur on day 1-day 35) ]
Blood and tissue sample collection for use in future basic and translational research studies
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title Biorepository for Precision Genomics
Official Title Collection of Specimens and Clinical Data to Create a Biorepository for Precision Genomics
Brief Summary This is a tissue collection protocol to create an annotated biorepository to support future basic and translational research. The study protocol and consent will request patient permission to allow their specimens to be stored for future use in other laboratory/correlative studies without requiring a separate new consent at a future date. It will include also a retrospective review of all patients who have been seen or treated by the Precision Genomics Clinic (waiver of consent requested). No specific research studies/aims are included directly in this proposal. Use of the samples, data, and other resources (cell lines, etc.) created within this protocol will require review/approval by the majority of the Precision Genomics Investigators and appropriate IRB approval.
Detailed Description Not Provided
Study Type Observational [Patient Registry]
Study Design Observational Model: Cohort
Time Perspective: Other
Target Follow-Up Duration 80 Years
Biospecimen Retention:   Samples With DNA
Prospective blood and tumor tissue samples will be collected. Retrospective review of patient charts for clinical information will also be done.
Sampling Method Non-Probability Sample
Study Population Patients who attend the Precision Genomics Clinic at Indiana University Health may elect to participate in this tissue and blood collection protocol.
Condition Neoplasms
  • Other: Blood sample collection
  • Other: Tumor tissue sample collection
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status Terminated
Actual Enrollment
 (submitted: November 11, 2020)
Original Estimated Enrollment
 (submitted: October 26, 2015)
Actual Study Completion Date July 7, 2020
Actual Primary Completion Date July 7, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  1. ≥ 18 years old at the time of informed consent
  2. Ability to provide written informed consent and HIPAA authorization
  3. Patients must have histologically or cytologically confirmed malignancy or related disorder. This includes patients with active disease as well as those in remission.
  4. One of the following tissue collection situations

    • Group 1: Patients having tissue collection for clinical reasons who are willing to have additional specimens taken for research (biopsy may be done under local anesthesia, intravenous conscious sedation, or general anesthesia, as clinically indicated)
    • Group 2: Patients willing to undergo tissue collection for the purpose of research only (biopsy may be done under local anesthesia or intravenous conscious sedation per the judgment of the treating physician). This may include collection of additional samples from patients undergoing a study-specific research biopsy/procedure. Patients in group 2 may not undergo general anesthesia as part of this protocol.
    • Group 3: Patients having tissue collection for clinical reasons who are willing to have excess tissue (i.e., tissue that would have otherwise been discarded) banked for research (biopsy may be done under local anesthesia, intravenous conscious sedation, or general anesthesia, as clinically indicated).
  5. Willingness to undergo phlebotomy for research blood samples Additional Criteria for Patients in Groups 1 and 2
  6. PT and PTT levels < 1.2 x the institutional ULN (PT, PTT not required for skin biopsies)
  7. Not receiving therapeutic anticoagulation
  8. Platelets ≥ 100 x 109/L

Exclusion Criteria:

  1. Concurrent disease or condition that would make the patient inappropriate for study participation or any serious medical or psychiatric disorder that would interfere with the subject's safety.
  2. Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.
  3. History of serious or life-threatening allergic reaction to local anesthetics (i.e. lidocaine, xylocaine)
  4. Any other condition, which in the opinion of the patient's treating oncologist or the physician performing the biopsy procedure, would make participation in this protocol unreasonably hazardous for the patient.

    Additional Criteria for Patients in Group 1 and 2

  5. Pregnant women are excluded from Groups 1 and 2 because there may be an increased risk to both mother and fetus in the setting of conscious sedation, which is required for biopsies of certain anatomic sites (e.g. liver, lung, bone). Also, ionizing radiation from CT-guided biopsies may pose a risk to the unborn fetus.
  6. Patients in Groups 1 and 2 may not have active cardiac disease, defined as:

    • History of uncontrolled or symptomatic angina
    • History of arrhythmias requiring medications, or clinically significant
    • Myocardial infarction < 6 months from study entry
    • Uncontrolled or symptomatic congestive heart failure
    • Any other cardiac condition, which in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient
  7. Patients in group 1 and 2 receiving bevacizumab or other angiogenesis inhibitors (or less than 6 weeks from last dose of an angiogenesis inhibitor) should not undergo a research core liver biopsy on this protocol because of the concern for the possibility of increased bleeding risk. Patients may undergo a research fine needle aspiration (FNA) of the liver as an alternative. Patients may also undergo core research biopsies of other sites, up to the discretion of the treating physician, but physicians should take the potential increased bleeding and/or delayed wound healing issues into consideration.
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
Administrative Information
NCT Number NCT02587026
Other Study ID Numbers IUSCC-0534
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Bryan Schneider, Indiana University
Study Sponsor Indiana University
Collaborators Not Provided
Principal Investigator: Bryan P Schneider, MD Vera Bradley Professor of Oncology, Professor of Medicine, Professor of Medical & Molecular Genetics
PRS Account Indiana University
Verification Date November 2020